Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Fungal Infection Reports
Erschienen in: Current Fungal Infection Reports 2/2020

16.05.2020 | Advances in Diagnosis of Invasive Fungal Infections (O Morrissey, Section Editor)

Diagnosis of Invasive Aspergillosis in Intensive Care Unit Patients

verfasst von: Lore Vanderbeke, Eric Van Wijngaerden, Johan Maertens, Joost Wauters, Katrien Lagrou

Erschienen in: Current Fungal Infection Reports | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Invasive aspergillosis is a frequent opportunistic infection in the intensive care unit. Diagnostic strategies within this setting are not well-defined.

Recent Findings

In the absence of histopathological proof, estimation of likelihood of disease is required, based on a combination of host factors with clinical, microbiological and radiologic findings. Importantly, the at-risk critically ill population has expanded beyond the classical immunosuppressed patients. Clinical features are non-specific, yet overt organ failure is associated with an increased risk and should raise the suspicion of invasive fungal disease. Validation of serological and molecular diagnostics is complicated by the lack of universal definitions in critically ill patients.

Summary

Improved awareness of novel risk groups can promote early diagnosis. Development of novel, host immune response driven biomarkers and universal definitions of invasive fungal disease in intensive care units is urgently needed.
Literatur
1.
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/invasive fungal infections cooperative group and the National Institute of Allergy and Infectious Diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813–21.PubMedPubMedCentral
2.
•• Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2019. https://​doi.​org/​10.​1093/​cid/​ciz1008Updated definitions of invasive fungal disease, incorporating evidence onAspergillusPCR.
3.
Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis. 2007;45(2):205–16.PubMed
4.
Taccone FS, Van den Abeele AM, Bulpa P, Misset B, Meersseman W, Cardoso T, et al. Epidemiology of invasive aspergillosis in critically ill patients: Clinical presentation, underlying conditions, and outcomes. Crit Care. 2015;19(1):7.PubMedPubMedCentral
5.
Vandewoude K, Blot S, Benoit D, Depuydt P, Vogelaers D, Colardyn F. Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality. Acta Clin Belg. 2004;59(5):251–7.PubMed
6.
Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, Leon C, Alvarez-Lerma F, Nolla-Salas J, et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care. 2005;9(3):R191–9.PubMedPubMedCentral
7.
Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007;30(4):782–800.PubMed
8.
Vandewoude KH, Blot SI, Depuydt P, Benoit D, Temmerman W, Colardyn F, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care. 2006;10(1):R31.PubMedPubMedCentral
9.
Blot SI, Taccone FS, Van den Abeele AM, Bulpa P, Meersseman W, Brusselaers N, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186(1):56–64.PubMed
10.
Husain S, Sole A, Alexander BD, Aslam S, Avery R, Benden C, et al. The 2015 International Society for Heart and Lung Transplantation guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: executive summary. J Heart Lung Transplant. 2016;35(3):261–82.PubMed
11.
Schroeder M, Simon M, Katchanov J, Wijaya C, Rohde H, Christner M, et al. Does galactomannan testing increase diagnostic accuracy for IPA in the ICU? A prospective observational study. Crit Care. 2016;20(1):139.PubMedPubMedCentral
12.
Koulenti D, Garnacho-Montero J, Blot S. Approach to invasive pulmonary aspergillosis in critically ill patients. Curr Opin Infect Dis. 2014;27(2):174–83.PubMed
13.
• Tejerina EE, Abril E, Padilla R, Rodriguez Ruiz C, Ballen A, Frutos-Vivar F, et al. Invasive aspergillosis in critically ill patients: an autopsy study. Mycoses. 2019;62(8):673–9 Recent autopsy study showing frequent misdiagnosis of IA in critically ill patients. PubMed
14.
Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Belleguic C, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis. 2006;43(5):577–84.PubMed
15.
Chakrabarti A, Kaur H, Savio J, Rudramurthy SM, Patel A, Shastri P, et al. Epidemiology and clinical outcomes of invasive mould infections in Indian intensive care units (FISF study). J Crit Care. 2019;51:64–70.PubMed
16.
•• Cavayas YA, Yusuff H, Porter R. Fungal infections in adult patients on extracorporeal life support. Crit Care. 2018;22(1):98. https://​doi.​org/​10.​1186/​s13054-018-2023-zRetrospective cohort study of adult patients on ECMO between 2006 and 2016, showing association betweenAspergillusinvolvement and use of ECMO as respiratory support as well as an association betweenAspergillusand influenza in this study cohort. CrossRefPubMedPubMedCentral
17.
•• Blot S, Rello J, Koulenti D. Diagnosing invasive pulmonary aspergillosis in ICU patients: putting the puzzle together. Curr Opin Crit Care. 2019;25(5):430–7 Comprehensive review of IPA in intensive care setting, attributing degrees of likelihood for invasive pulmonary fungal disease to different pillars of diagnosis. PubMed
18.
Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and Management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60.PubMedPubMedCentral
19.
Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170(6):621–5.PubMed
20.
21.
Levesque E, Ait-Ammar N, Dudau D, Clavieras N, Feray C, Foulet F, et al. Invasive pulmonary aspergillosis in cirrhotic patients: analysis of a 10-year clinical experience. Ann Intensive Care. 2019;9(1):31.PubMedPubMedCentral
22.
23.
• Danion F, Rouzaud C, Dureault A, Poiree S, Bougnoux ME, Alanio A, et al. Why are so many cases of invasive aspergillosis missed? Med Mycol. 2019;57(Supplement_2):S94–s103 Elaborate review of causes of IA misdiagnosis in a general population, focussing on the different aspects of diagnosis (host factors, radiology and microbiological tests). PubMed
24.
Wauters J, Baar I, Meersseman P, Meersseman W, Dams K, De Paep R, et al. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med. 2012;38(11):1761–8.PubMedPubMedCentral
25.
van de Veerdonk FL, Kolwijck E, Lestrade PP, Hodiamont CJ, Rijnders BJ, van Paassen J, et al. Influenza-associated Aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2017;196(4):524–7.PubMed
26.
• Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782–92 This retrospective cohort study of multiple ICUs in Belgium and the Netherlands showed for the first time that severe influenza in critically ill patients is an independent risk factor for IPA development. PubMed
27.
Baron M, Zini JM, Challan Belval T, Vignon M, Denis B, Alanio A, et al. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. Leuk Lymphoma. 2017;58(12):2981–2.PubMed
28.
Fujita K, Kim YH, Kanai O, Yoshida H, Mio T, Hirai T. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy. Respir Med. 2019;146:66–70.PubMed
29.
Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70(4):616–23.PubMed
30.
Prebil SE, Andrews J, Cribbs SK, Martin GS, Esper A. Safety of research bronchoscopy in critically ill patients. J Crit Care. 2014;29(6):961–4.PubMedPubMedCentral
31.
Prattes J, Flick H, Pruller F, Koidl C, Raggam RB, Palfner M, et al. Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases. Am J Respir Crit Care Med. 2014;190(8):922–9.PubMed
32.
He H, Ding L, Sun B, Li F, Zhan Q. Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective study. Crit Care. 2012;16(4):R138.PubMedPubMedCentral
33.
Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1–e38.PubMed
34.
35.
Chong GM, Maertens JA, Lagrou K, Driessen GJ, Cornelissen JJ, Rijnders BJ. Diagnostic performance of Galactomannan antigen testing in cerebrospinal fluid. J Clin Microbiol. 2016;54(2):428–31.PubMedPubMedCentral
36.
37.
38.
Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008;177(1):27–34.PubMed
39.
Fortun J, Martin-Davila P, de la Gomez Garcia Pedrosa E, Silva JT, Garcia-Rodriguez J, Benito D, et al. Galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis in non-hematological patients. J Inf Secur. 2016;72(6):738–44.
40.
Khodavaisy S, Hedayati MT, Alialy M, Habibi MR, Badali H. Detection of galactomannan in bronchoalveolar lavage of the intensive care unit patients at risk for invasive aspergillosis. Curr Med Mycol. 2015;1(1):12–7.PubMedPubMedCentral
41.
Acosta J, Catalan M, del Palacio-Perez-Medel A, Lora D, Montejo JC, Cuetara MS, et al. A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1--> 3)-beta-d-glucan chromogenic assay in serum samples. Clin Microbiol Infect. 2011;17(7):1053–60.PubMed
42.
Petraitiene R, Petraitis V, Witt JR 3rd, Durkin MM, Bacher JD, Wheat LJ, et al. Galactomannan antigenemia after infusion of gluconate-containing plasma-Lyte. J Clin Microbiol. 2011;49(12):4330–2.PubMedPubMedCentral
43.
Spriet I, Lagrou K, Maertens J, Willems L, Wilmer A, Wauters J. Plasmalyte: no longer a culprit in causing false-positive Galactomannan test results. J Clin Microbiol. 2016;54(3):795–7.PubMedPubMedCentral
44.
Aigner M, Wanner M, Kreidl P, Lass-Florl C, Lackner M. Candida in the Respiratory Tract Potentially Triggers Galactomannan Positivity in Nonhematological Patients. Antimicrob Agents Chemother. 2019;63(6):e00138–19.PubMedPubMedCentral
45.
• Hage CA, Carmona EM, Epelbaum O, Evans SE, Gabe LM, Haydour Q, et al. Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2019;200(5):535–50 Novel guideline of the American Thoracic Society focussing on microbiological aspects of invasive fungal disease in pulmonary and critical care setting. This paper entails specific recommendations on use of galactomannan andAspergillusPCR for IA diagnosis. PubMed
46.
Acosta J, Catalan M, del Palacio-Perez-Medel A, Montejo JC, De-La-Cruz-Bertolo J, Moragues MD, et al. Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)-beta-D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease. Eur J Clin Microbiol Infect Dis. 2012;31(5):721–31.PubMed
47.
• Boch T, Reinwald M, Spiess B, Liebregts T, Schellongowski P, Meybohm P, et al. Detection of invasive pulmonary aspergillosis in critically ill patients by combined use of conventional culture, galactomannan, 1–3-beta-D-glucan and Aspergillus specific nested polymerase chain reaction in a prospective pilot study. J Crit Care. 2018;47:198–203 Prospective pilot study of a combination biomarker diagnostic strategy in 44 critically ill patients, both hematological as non-hematological, showing a benefit of integrating BAL and blood sample biomarkers for diagnosis of IPA. PubMed
48.
De Vlieger G, Lagrou K, Maertens J, Verbeken E, Meersseman W, Van Wijngaerden E. Beta-D-glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised critically ill patients with symptoms of respiratory infection: an autopsy-based study. J Clin Microbiol. 2011;49(11):3783–7.PubMedPubMedCentral
49.
Lahmer T, Neuenhahn M, Held J, Rasch S, Schmid RM, Huber W. Comparison of 1,3-beta-d-glucan with galactomannan in serum and bronchoalveolar fluid for the detection of Aspergillus species in immunosuppressed mechanical ventilated critically ill patients. J Crit Care. 2016;36:259–64.PubMed
50.
Hoenigl M, Prattes J, Spiess B, Wagner J, Prueller F, Raggam RB, et al. Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol. 2014;52(6):2039–45.PubMedPubMedCentral
51.
Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med. 2009;35(9):1526–31.PubMed
52.
Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol. 2003;10(5):882–5.PubMedPubMedCentral
53.
Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB. The (1,3){beta}-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol. 2010;48(11):4083–8.PubMedPubMedCentral
54.
Hummel M, Spiess B, Kentouche K, Niggemann S, Bohm C, Reuter S, et al. Detection of Aspergillus DNA in cerebrospinal fluid from patients with cerebral aspergillosis by a nested PCR assay. J Clin Microbiol. 2006;44(11):3989–93.PubMedPubMedCentral
55.
Imbert S, Brossas JY, Palous M, Joly I, Meyer I, Fekkar A. Performance of Aspergillus PCR in cerebrospinal fluid for the diagnosis of cerebral aspergillosis. Clin Microbiol Infect. 2017;23(11):889.e1–4.
56.
White PL, Wingard JR, Bretagne S, Loffler J, Patterson TF, Slavin MA, et al. Aspergillus polymerase chain reaction: systematic review of evidence for clinical use in comparison with antigen testing. Clin Infect Dis. 2015;61(8):1293–303.PubMedPubMedCentral
57.
Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(2):89–96.PubMed
58.
Imbert S, Gauthier L, Joly I, Brossas JY, Uzunov M, Touafek F, et al. Aspergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients. Clin Microbiol Infect. 2016;22(6):562.e1–8.
59.
Orsi CF, Gennari W, Venturelli C, La Regina A, Pecorari M, Righi E, et al. Performance of 2 commercial real-time polymerase chain reaction assays for the detection of Aspergillus and Pneumocystis DNA in bronchoalveolar lavage fluid samples from critical care patients. Diagn Microbiol Infect Dis. 2012;73(2):138–43.PubMed
60.
Torelli R, Sanguinetti M, Moody A, Pagano L, Caira M, De Carolis E, et al. Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay. J Clin Microbiol. 2011;49(12):4273–8.PubMedPubMedCentral
61.
Thornton CR. Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol. 2008;15(7):1095–105.PubMedPubMedCentral
62.
Eigl S, Prattes J, Lackner M, Willinger B, Spiess B, Reinwald M, et al. Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients. Crit Care. 2015;19:178.PubMedPubMedCentral
63.
Hoenigl M, Eigl S, Heldt S, Duettmann W, Thornton C, Prattes J. Clinical evaluation of the newly formatted lateral-flow device for invasive pulmonary aspergillosis. Mycoses. 2018;61(1):40–3.PubMed
64.
• Mercier T, Dunbar A, de Kort E, Schauwvlieghe A, Reynders M, Guldentops E, et al. Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study. Med Mycol. 2019. https://​doi.​org/​10.​1093/​mmy/​myz079Comparative study of current CE-marked lateral flow assays for IPA diagnosis, evaluated in a multicenter study of hematological patients.
65.
Jenks JD, Mehta SR, Taplitz R, Aslam S, Reed SL, Hoenigl M. Point-of-care diagnosis of invasive aspergillosis in non-neutropenic patients: Aspergillus Galactomannan lateral flow assay versus Aspergillus-specific lateral flow device test in bronchoalveolar lavage. Mycoses. 2019;62(3):230–6.PubMedPubMedCentral
66.
Kabbani D, Bhaskaran A, Singer LG, Bhimji A, Rotstein C, Keshavjee S, et al. Pentraxin 3 levels in bronchoalveolar lavage fluid of lung transplant recipients with invasive aspergillosis. J Heart Lung Transplant. 2017;36(9):973–9.PubMed
67.
Li H, Liu L, Zhou W, Rui Y, He B, Shi Y, et al. Pentraxin 3 in bronchoalveolar lavage fluid and plasma in non-neutropenic patients with pulmonary aspergillosis. Clin Microbiol Infect. 2019;25(4):504–10.PubMed
68.
Heldt S, Eigl S, Prattes J, Flick H, Rabensteiner J, Pruller F, et al. Levels of interleukin (IL)-6 and IL-8 are elevated in serum and bronchoalveolar lavage fluid of haematological patients with invasive pulmonary aspergillosis. Mycoses. 2017;60(12):818–25.PubMed
69.
Rawlings SA, Heldt S, Prattes J, Eigl S, Jenks JD, Flick H, et al. Using interleukin 6 and 8 in blood and Bronchoalveolar lavage fluid to predict survival in hematological malignancy patients with suspected pulmonary Mold infection. Front Immunol. 2019;10:1798.PubMedPubMedCentral
70.
Heldt S, Prattes J, Eigl S, Spiess B, Flick H, Rabensteiner J, et al. Diagnosis of invasive aspergillosis in hematological malignancy patients: performance of cytokines, asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. J Inf Secur. 2018;77(3):235–41.
71.
Bacher P, Steinbach A, Kniemeyer O, Hamprecht A, Assenmacher M, Vehreschild MJ, et al. Fungus-specific CD4(+) T cells for rapid identification of invasive pulmonary mold infection. Am J Respir Crit Care Med. 2015;191(3):348–52.PubMed
72.
Steinbach A, Cornely OA, Wisplinghoff H, Schauss AC, Vehreschild JJ, Rybniker J, et al. Mould-reactive T cells for the diagnosis of invasive mould infection-a prospective study. Mycoses. 2019;62(7):562–9.PubMed
73.
• Jenks JD, Rawlings SA, Garcia-Vidal C, Koehler P, Mercier T, Prattes J, et al. Immune parameters for diagnosis and treatment monitoring in invasive Mold infection. J Fungi (Basel). 2019;5(4):116. https://​doi.​org/​10.​3390/​jof5040116Elaborate review on recent advances in immunological diagnostic tools for invasive fungal disease. CrossRef
74.
Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001;19(1):253–9.PubMed
75.
Park SY, Lim C, Lee SO, Choi SH, Kim YS, Woo JH, et al. Computed tomography findings in invasive pulmonary aspergillosis in non-neutropenic transplant recipients and neutropenic patients, and their prognostic value. J Inf Secur. 2011;63(6):447–56.
76.
Huang L, He H, Ding Y, Jin J, Zhan Q. Values of radiological examinations for the diagnosis and prognosis of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary diseases. Clin Respir J. 2018;12(2):499–509.PubMed
77.
Krenke R, Grabczak EM. Tracheobronchial manifestations of Aspergillus infections. Sci World J. 2011;11:2310–29.
78.
Thornton CR. Molecular imaging of invasive pulmonary Aspergillosis using ImmunoPET/MRI: the future looks bright. Front Microbiol. 2018;9:691.PubMedPubMedCentral
79.
Munoz P, Vena A, Ceron I, Valerio M, Palomo J, Guinea J, et al. Invasive pulmonary aspergillosis in heart transplant recipients: two radiologic patterns with a different prognosis. J Heart Lung Transplant. 2014;33(10):1034–40.PubMed
80.
81.
•• Bassetti M, Scudeller L, Giacobbe DR, Lamoth F, Righi E, Zuccaro V, et al. Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections definitions in ICU patients (FUNDICU) project. Mycoses. 2019;62(4):310–9 Protocol of project aimed to develop definitions for invasive fungal diseases in intensive care setting. PubMed
Metadaten
Titel
Diagnosis of Invasive Aspergillosis in Intensive Care Unit Patients
verfasst von
Lore Vanderbeke
Eric Van Wijngaerden
Johan Maertens
Joost Wauters
Katrien Lagrou
Publikationsdatum
16.05.2020
Verlag
Springer US
Erschienen in
Current Fungal Infection Reports / Ausgabe 2/2020
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-020-00383-6

Weitere Artikel der Ausgabe 2/2020

Current Fungal Infection Reports 2/2020 Zur Ausgabe

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz and M Pereira, Section Editors)

Coccidioidomycosis in Children and Adolescents: an Update

Clinical Pathology (S Challa, Section Editor)

Invasive Fungal Infections of the Central Nervous System in Immune-Competent Hosts

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz and M Pereira, Section Editors)

Skin Infections Caused by Emerging Candida Species

Pharmacology and Pharmacodynamics of Antifungal Agents (J Amsden, Section Editor)

Updates in the Treatment of Breakthrough Mold Infections

Clinical Mycology Lab Issues (S Cordoba, Section Editor)

Should Etest MICs for Yeasts Be Categorized by Reference (BPs/ECVs) or by Etest (ECVs) Cutoffs as Determinants of Emerging Resistance?

Clinical Mycology Lab Issues (S Cordoba, Section Editor)

Mycetomas in the Endemic Area of Argentina

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise